Pfizer Inc (PFE): Today's Featured Drugs Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Pfizer ( PFE) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day down 0.4%. By the end of trading, Pfizer fell $0.61 (-1.9%) to $31.22 on average volume. Throughout the day, 35,458,315 shares of Pfizer exchanged hands as compared to its average daily volume of 25,289,800 shares. The stock ranged in price between $31.16-$31.71 after having opened the day at $31.69 as compared to the previous trading day's close of $31.83. Other companies within the Drugs industry that declined today were: Mast Therapeutics ( MSTX), down 39.4%, Echo Therapeutics ( ECTE), down 17.2%, PDL BioPharma ( PDLI), down 11.2% and Biostar Pharmaceuticals ( BSPM), down 8.8%.

Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells medicines for people and animals worldwide. Pfizer has a market cap of $205.6 billion and is part of the health care sector. The company has a P/E ratio of 21.0, above the S&P 500 P/E ratio of 17.7. Shares are up 26.5% year to date as of the close of trading on Monday. Currently there are 8 analysts that rate Pfizer a buy, 1 analyst rates it a sell, and 3 rate it a hold.

TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, solid stock price performance, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the positive front, OncoMed Pharmaceuticals ( OMED), up 97.9%, Conatus Pharmaceuticals ( CNAT), up 18.1%, Galectin Therapeutics ( GALT), up 13.2% and Prima Biomed ( PBMD), up 11.8% , were all gainers within the drugs industry with Seattle Genetics ( SGEN) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.
null

If you liked this article you might like

Profit With Technical Analysis: Cramer's 'Mad Money' Recap (Tuesday 2/20/18)

Profit With Technical Analysis: Cramer's 'Mad Money' Recap (Tuesday 2/20/18)

Jim Cramer: These 4 Stocks Seem Attractive Right Here

Jim Cramer: These 4 Stocks Seem Attractive Right Here

3 Reasons Pfizer May Want to Buy Bristol-Myers Squibb

3 Reasons Pfizer May Want to Buy Bristol-Myers Squibb

With the Correction In Pfizer Behind Us, Traders Can Go Long Again

With the Correction In Pfizer Behind Us, Traders Can Go Long Again

Axovant Shares Crater as CEO and President Both Resign

Axovant Shares Crater as CEO and President Both Resign